Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 8Phase NA 5Phase EARLY_PHASE1 2Phase 1/2 2

Status

Terminated 2Completed 2Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Sarcoma 1

Conditions

Sarcoma, Ewing 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 142Gemcitabine 129Paclitaxel 125Radiotherapy 119Carboplatin 112Cisplatin 111pembrolizumab 110Nivolumab 106Docetaxel 90Rituximab 86Lenalidomide 77Dexamethasone 76Cytarabine 69Bevacizumab 64Fluorouracil 63Etoposide 63Oxaliplatin 62Filgrastim 59Peripheral Blood Stem Cell Transplantation 58Everolimus 58Capecitabine 58fludarabine phosphate 57Doxorubicin 56Temozolomide 55Prednisone 54Irinotecan 53Cetuximab 50fludarabine 48Ipilimumab 48Erlotinib Hydrochloride 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × alovudine × Clear all
NCT04067115 2025-12-17

U01CA236220

Sarcoma Alliance for Research through Collaboration

Phase 1/2 Completed
37 enrolled
Sarcoma

Sarcoma, Ewing

NCT00453362 2017-03-31

A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib

Genentech, Inc.

Phase 1/2 Completed
88 enrolled 18 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡